The Article related to butanoic acid heteroaryl derivative preparation integrin receptor antagonist, alkanoic acid heteroaryl derivative preparation integrin receptor antagonist, Aliphatic Compounds: Carboxylic Acids and Peroxycarboxylic Acids and Their Sulfur-Containing Analogs and Salts and other aspects.COA of Formula: C8H9BrN2O2
On July 15, 2004, Boys, Mark L.; Schretzman, Lori A.; Tollefson, Michael B.; Chandrakumar, Nizal S.; Khanna, Ish K.; Nguyen, Maria; Downs, Victoria; Mohler, Scott B.; Gesicki, Glen J.; Penning, Thomas D.; Chen, Barbara B.; Wang, Yaping; Khilevich, Albert; Desai, Bipinchandra N.; Yu, Yi; Wendt, John A.; Stenmark, Heather; Wu, Lisa; Huff, Renee M.; Nagarajan, Srinivasan R.; Devadas, Balekudru; Lu, Hwang-fun; Russell, Mark; Spangler, Dale P.; Parikh, Mihir D.; Clare, Michael published a patent.COA of Formula: C8H9BrN2O2 The title of the patent was Heteroarylalkanoic acids as integrin receptor antagonists. And the patent contained the following:
The present invention relates to pharmaceutical compositions comprising compounds I [A = (un)saturated and/or (un)substituted 4-8 membered monocyclic or 7-12 membered bicyclic ring, containing 1 to 5 heteroatoms selected from the group consisting of O, N or S; ring A may further contain a carboxamide, sulfone, sulfonamide, or an acyl group; A1 = (un)saturated and/or (un)substituted 5-9 membered monocyclic or 8-14 membered polycyclic heterocycle containing at least one N; or A1 = substituted urea, iminourea or thiourea alicyclic or cyclic analog; Z1 = CH2, CH2O, O, NH, CO, S, SO, CHOH, SO2; Z2 = (un)substituted 1-5 carbon linker optionally containing one or more heteroatoms; alternatively Z1-Z2 may contain a carboxamide, sulfone, sulfonamide, alkenyl, acyl group, or aryl or heteroaryl ring; X = CO, SO2, S, O, substituted amine, substituted CH; Y = CO, SO2, substituted amine, etc.; Y5 = C or N; Y3 and Y4 independently = H, halo, (un)substituted-alkyl, -aryl, -alkene, etc.; or Y3 and Y4 together form a (un)saturated and/or (un)substituted 3-8 membered monocyclic or a 7-11 membered bicyclic ring optionally containing heteroatoms; or X and Y3 form a 3-7 membered monocyclic ring optionally containing heteroatoms; Rb = OH, alkoxy, arylamine, etc.], or a pharmaceutically acceptable salt thereof, methods of selectively inhibiting or antagonizing the ανβ3 and/or the ανβ5 integrin without significantly inhibiting the ανβ6 integrin, and methods to prepare I. Thus, e.g., II was prepared in four steps with oxadiazole ring forming via cyclization reaction of amide oxime III with cyclic anhydride IV (preparation given). I antagonize αvβ3 integrin with an IC50 values ranging from 0.1 nM to 100 μM in the 293-cell assay. Similarly, I also antagonized αvβ5 integrin with an IC50 values of < 50 μM in the cell adhesion assay. The experimental process involved the reaction of 3-((6-Bromopyridin-2-yl)amino)propanoic acid(cas: 68638-67-5).COA of Formula: C8H9BrN2O2
The Article related to butanoic acid heteroaryl derivative preparation integrin receptor antagonist, alkanoic acid heteroaryl derivative preparation integrin receptor antagonist, Aliphatic Compounds: Carboxylic Acids and Peroxycarboxylic Acids and Their Sulfur-Containing Analogs and Salts and other aspects.COA of Formula: C8H9BrN2O2
Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem